The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

20/05/2015
02/10/2026
EU PAS number:
EUPAS9771
Study
Finalised
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS9771

Study ID

9772

Official title and acronym

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

DARWIN EU® study

No

Study countries

United States

Study description

This study is of a retrospective cohort design with propensity score matching. The primary study objective is to assess the safety and effectiveness of dabigatran compared to warfarin in patients diagnosed with non-valvular atrial fibrillation in the DoD population.

Study status

Finalised
Research institutions and networks

Institutions

PPD Evidera
Sweden
United Kingdom
United States
First published:
22/09/2025
Institution Laboratory/Research/Testing facility Non-Pharmaceutical company ENCePP partner

Contact details

Evidera Evidera

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Pharmaceuticals, Inc.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable